Log in
Sign up
Synthorx

Synthorx

Synthetic biology company that created novel DNA base pairs and uses them to incorporate novel amino acids into proteins for potential therapeutics in areas of cancer and autoimmune disorders.

OverviewStructured DataIssuesContributorsActivity
Contents

Formerly known as Alinos, Synthorx changed its name in 2014. The company created novel DNA base pairs d5SICSTP and dNaMTP (abbreviated X–Y) which can be replicated, maintained, transcribed and translated in vivo. Synthorx has a proprietary bacterial strain based on the E. coli manufacturing strain which expresses a nucleotide transporter that allows controllable maintenance of X-Y genetic information. Synthorin proteins are produced by the cell’s natural translation machinery using supplied and engineered components so that the X-Y codons are decoded by introducing novel amino acids.

The addition of X and Y to the genetic alphabet allows increased storage of information and the ability to incorporate novel amino acids into proteins. Synthorx is using its technology to address limitations of working with the twenty natural amino acids in protein therapeutics. For example, proteins can have dual and opposing functions due to interactions with different receptors. Synthorx can use the novel expanded genetic alphabet to create proteins capable of re-programming receptor interactions to potentially treat disease.

Pipeline
THOR-707

THOR-707 was designed to have advantages of current IL-2 therapies. THOR-707 is a variant of recombinant human IL-2 that is pegylated at one site so that it blocks engagement of the high affinity IL-2 receptor alpha chain. This extends the half-life of the drug and increases tumor distribution and retention. THOR-707 is designed to kill tumor cells by increasing CD8+ and NK cells while avoiding vascular leak syndrome.

Phase 1 and 2 clinical trials are testing THOR-707 as a single agent and in combination with Checkpoint Inhibitors.

IL-2 autoimmune (AI) Synthorin

IL-2 autoimmune (AI) Synthorin is developed for autoimmune disorders. IL-2 can dampen immune-cell activation but the short half-life of low dose IL-2 is impractical to administer for treatment of chronic autoimmune disorders. IL-2 AI Synthorin is being developed to overcome this limitation to treat chronic graft versus host disease (GVHD), atopic dermatitis and Crohn’s disease.

Timeline

Funding Rounds

Open in Query Tool

Products

Open in Query Tool

Acquisitions

Open in Query Tool

SBIR/STTR Awards

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date

References

synthorx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Therapeutics
Therapeutics
Autoimmune disease
Autoimmune disease
Biomedical engineering
Biomedical engineering
Technology
Technology
Synthetic biology
Synthetic biology
Biology
Biology
...
Location
‌
La Jolla, Placentia, California
San Diego
San Diego
B2X
B2C
B2C
Founder
‌
Floyd Romesberg
Date Incorporated
2014
Investors
Osage University Partners
Osage University Partners
Avalon Ventures
Avalon Ventures
Medicxi Ventures
Medicxi Ventures
RA Capital Management
RA Capital Management
Correlation Ventures
Correlation Ventures
OrbiMed
OrbiMed
Founded Date
2014
Total Funding Amount (USD)
152,000,000
Latest Funding Round Date
April 30, 2018
Glassdoor ID
2391392
Latest Funding Type
‌
Series C round
Wellfound ID
synthorx

Other attributes

Company Operating Status
Active
Country
United States
United States
Latest Funding Round Amount (USD)
63,000,000

Find more companies like Synthorx

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.